Literature DB >> 25677736

Changes in neuropsychological function after treatment with metacognitive therapy or cognitive behavior therapy for depression.

Samantha J Groves1,2, Richard J Porter1,3, Jennifer Jordan1,3, Robert Knight2, Janet D Carter4, Virginia V W McIntosh3, Kumari Fernando5, Christopher M A Frampton1, Roger T Mulder1,3, Cameron Lacey1,3, Peter R Joyce1.   

Abstract

BACKGROUND: Metacognitive therapy (MCT) is an innovative treatment model addressing patterns of negative thinking seen in emotional disorders. Unlike cognitive behavior therapy (CBT), MCT has strategies targeting dysfunctional cognitive and metacognitive processes underlying perseverative thinking patterns and attentional biases. The aim of this pilot study was to compare changes in neuropsychological functioning related to executive function and attention in outpatients with depression following treatment with MCT or CBT.
METHODS: Forty-eight participants referred for outpatient treatment of depression were randomized to 12 weeks of MCT (n = 23) or CBT (n = 25). Mood severity and neuropsychological functioning were assessed at pretreatment, 4 weeks, and at end treatment (12 weeks).
RESULTS: There were no significant group differences at pretreatment or 4 weeks on any neuropsychological test, although overall both groups showed a small improvement by 4 weeks. At end treatment, the MCT group demonstrated significantly greater improvement in performance on a task requiring spatial working memory and attention than the CBT group. Changes in executive functioning and attention were independent of change in mood symptoms.
CONCLUSIONS: MCT may have an advantage over CBT in improving aspects of executive function, including attention. MCT's emphasis on attentional training and flexible control of thinking may have a beneficial effect on neuropsychological functioning, consistent with the purported mechanism of action.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  cognition; cognitive behavior therapy; depression; treatment

Mesh:

Year:  2015        PMID: 25677736     DOI: 10.1002/da.22341

Source DB:  PubMed          Journal:  Depress Anxiety        ISSN: 1091-4269            Impact factor:   6.505


  8 in total

1.  Dysfunctional Metacognitive Beliefs Are Associated with Decreased Executive Control.

Authors:  Brage Kraft; Rune Jonassen; Tore C Stiles; Nils I Landrø
Journal:  Front Psychol       Date:  2017-04-19

2.  Metacognitive Therapy for Depression in Adults: A Waiting List Randomized Controlled Trial with Six Months Follow-Up.

Authors:  Roger Hagen; Odin Hjemdal; Stian Solem; Leif Edward Ottesen Kennair; Hans M Nordahl; Peter Fisher; Adrian Wells
Journal:  Front Psychol       Date:  2017-01-24

3.  Clinical and methodological considerations for psychological treatment of cognitive impairment in major depressive disorder.

Authors:  Katie M Douglas; Melissa Milanovic; Richard J Porter; Christopher R Bowie
Journal:  BJPsych Open       Date:  2020-06-29

4.  A test of the goodness of fit of the generic metacognitive model of psychopathology symptoms.

Authors:  Henrik Nordahl; Ingunn Harsvik Ødegaard; Odin Hjemdal; Adrian Wells
Journal:  BMC Psychiatry       Date:  2019-09-18       Impact factor: 3.630

5.  A Comparison of Metacognitive Therapy in Current Versus Persistent Depressive Disorder - A Pilot Outpatient Study.

Authors:  Lotta Winter; Julia Gottschalk; Janina Nielsen; Adrian Wells; Ulrich Schweiger; Kai G Kahl
Journal:  Front Psychol       Date:  2019-08-06

6.  Randomised controlled trial of Interpersonal and Social Rhythm Therapy and group-based Cognitive Remediation versus Interpersonal and Social Rhythm Therapy alone for mood disorders: study protocol.

Authors:  Katie M Douglas; Maree L Inder; Marie T Crowe; Jennifer Jordan; Dave Carlye; Cameron Lacey; Ben Beaglehole; Roger Mulder; Kate Eggleston; Katherine A Donovan; Christopher M A Frampton; Christopher R Bowie; Richard J Porter
Journal:  BMC Psychiatry       Date:  2022-02-14       Impact factor: 3.630

7.  Activation therapy for the treatment of inpatients with depression - protocol for a randomised control trial compared to treatment as usual.

Authors:  Ian R E Averill; Ben Beaglehole; Katie M Douglas; Jennifer Jordan; Marie T Crowe; Maree Inder; Cameron J Lacey; Christopher M Frampton; Christopher R Bowie; Richard J Porter
Journal:  BMC Psychiatry       Date:  2019-02-01       Impact factor: 3.630

8.  Citalopram and metacognitive therapy for depressive symptoms and cognitive emotion regulation in patients with major depressive disorder: A randomized controlled trial.

Authors:  Gholam Reza Kheirabadi; Zahra Yousefian; Fatemeh Zargar; Mahboobe Bahrami; Mohammad R Maracy
Journal:  J Educ Health Promot       Date:  2020-01-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.